Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL.

Francine M. Foss,Christiane Querfeld,Youn H. Kim,Lauren Pinter-Brown,Basem M. William,Pierluigi Porcu,Theresa R. Pacheco,Bradley M. Haverkos,Jennifer DeSimone,Joan Guitart,Ahmad Halwani,Herbert Eradat,Auris Huen,Anita Seto,Linda A Pestano,Gilad Shalag Gordon,Diana Escolar,Paul Rubin,William Marshall,Jud Williams

Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL.

2018

2511Background: MRG-106 is an inhibitor of miR-155, a microRNA with a strong link to CTCL pathogenesis. The goals of this FIH study are to evaluate the safety, tolerability, PK, and efficacy of MRG...

Keywords:

Pathology
Cancer research
miR-155
Medicine
Tolerability
Pathogenesis
microRNA

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations